



(51) International Patent Classification:

C07D 401/14 (2006.01) **C07D 407/14** (2006.01)
C07D 413/14 (2006.01) **C07D 413/04** (2006.01)
A61K 31/454 (2006.01) **C07D 417/14** (2006.01)
A61K 31/497 (2006.01) **C07D 471/04** (2006.01)
A61K 31/506 (2006.01) **C07D 487/04** (2006.01)
A61K 31/519 (2006.01) **A61P 29/02** (2006.01)
A61K 31/535 (2006.01) **A61P 37/08** (2006.01)
C07D 401/04 (2006.01)

(21) International Application Number:

PCT/IB2014/063383

(22) International Filing Date:

24 July 2014 (24.07.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/861,709 2 August 2013 (02.08.2013) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **BLINN, James, Robert**; 693 Rolling Thunder Drive, O'Fallon, Missouri 63368 (US). **FLICK, Andrew, Christopher**; 49 Economy Road, Westbrook, Connecticut 06498 (US). **WENNERSTÄL, Göran, Mattias**; Sankt Mickelsgatan 149, SE-129 44 Hägersten (SE). **JONES, Peter**; 61 Henderson Street, Arlington, Massachusetts 02474 (US). **KAILA, Neelu**; 17 Augustus Road, Lexington, Massachusetts 02421 (US). **KIEFER, James, Richard, Jr.**; 2618 Prindle Road, Belmont, California 94002 (US). **KURUMBAIL, Ravi, G.**; 4 Harvest Glen,

East Lyme, Connecticut 06333 (US). **MENTE, Scot, Richard**; 48 Arlmont Street, Arlington, Massachusetts 02476 (US). **MEYERS, Marvin, Jay**; 314 Oak Creek Farm Ct., Wentzville, Missouri 63385 (US). **SCHNUTE, Mark, Edward**; 10 Chase Path, Acton, Massachusetts 01720 (US). **THORARENSEN, Atli**; 581 Great Road, Stow, Massachusetts 01775 (US). **XING, Li**; 8 Great Rock Road, Lexington, Massachusetts 02421 (US). **ZAMAR-ATSKI, Edouard**; Fredsgatan 2 B, SE-753 13 Uppsala (SE). **ZAPF, Christoph, Wolfgang**; 48 Kinder Circle, Marlborough, Massachusetts 01752 (US).


(74) Agent: **KLEIMAN, Gabriel, L.**; Pfizer Inc., 235 East 42nd. Street, Mail Stop 235/9/64, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF



(57) Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR γ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

14 May 2015